Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMRN NYSE:JNJ NASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMRNBioMarin Pharmaceutical$57.77+1.8%$58.14$52.93▼$86.04$11.09B0.351.78 million shs1.46 million shsJNJJohnson & Johnson$178.20-0.3%$168.57$140.68▼$181.16$429.72B0.47.56 million shs9.73 million shsVRTXVertex Pharmaceuticals$396.12-0.2%$428.49$362.50▼$519.88$101.56B0.441.68 million shs1.17 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMRNBioMarin Pharmaceutical0.00%-0.86%-2.84%+1.98%-35.71%JNJJohnson & Johnson0.00%+0.62%+3.96%+14.95%+6.53%VRTXVertex Pharmaceuticals0.00%+1.30%+5.45%-12.07%-17.23%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMRNBioMarin Pharmaceutical$57.77+1.8%$58.14$52.93▼$86.04$11.09B0.351.78 million shs1.46 million shsJNJJohnson & Johnson$178.20-0.3%$168.57$140.68▼$181.16$429.72B0.47.56 million shs9.73 million shsVRTXVertex Pharmaceuticals$396.12-0.2%$428.49$362.50▼$519.88$101.56B0.441.68 million shs1.17 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMRNBioMarin Pharmaceutical0.00%-0.86%-2.84%+1.98%-35.71%JNJJohnson & Johnson0.00%+0.62%+3.96%+14.95%+6.53%VRTXVertex Pharmaceuticals0.00%+1.30%+5.45%-12.07%-17.23%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMRNBioMarin Pharmaceutical 2.72Moderate Buy$93.4361.74% UpsideJNJJohnson & Johnson 2.65Moderate Buy$176.29-1.07% DownsideVRTXVertex Pharmaceuticals 2.56Moderate Buy$497.1025.49% UpsideCurrent Analyst Ratings BreakdownLatest BMRN, VRTX, and JNJ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025BMRNBioMarin PharmaceuticalRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$85.009/2/2025VRTXVertex PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Perform8/21/2025JNJJohnson & JohnsonCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$185.00 ➝ $200.008/13/2025BMRNBioMarin PharmaceuticalZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/6/2025BMRNBioMarin PharmaceuticalGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$101.00 ➝ $106.008/6/2025VRTXVertex PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$424.00 ➝ $411.008/6/2025VRTXVertex PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$558.00 ➝ $546.008/6/2025VRTXVertex PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$460.008/5/2025BMRNBioMarin PharmaceuticalWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$94.008/5/2025BMRNBioMarin PharmaceuticalUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$113.00 ➝ $114.008/5/2025VRTXVertex PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$442.00 ➝ $438.00(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMRNBioMarin Pharmaceutical$3.06B3.62$3.25 per share17.80$29.69 per share1.95JNJJohnson & Johnson$88.82B4.83$13.10 per share13.60$29.69 per share6.00VRTXVertex Pharmaceuticals$11.02B9.22N/AN/A$63.72 per share6.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMRNBioMarin Pharmaceutical$426.86M$3.3717.1413.250.7421.45%12.59%10.13%11/4/2025 (Estimated)JNJJohnson & Johnson$14.07B$9.3519.0616.102.2725.00%32.49%13.00%10/14/2025 (Estimated)VRTXVertex Pharmaceuticals-$535.60M$13.9928.3122.62N/A31.86%23.91%17.14%11/3/2025 (Estimated)Latest BMRN, VRTX, and JNJ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025VRTXVertex Pharmaceuticals$4.24$4.52+$0.28$3.99$2.90 billion$2.94 billion7/16/2025Q2 2025JNJJohnson & Johnson$2.68$2.77+$0.09$2.29$22.85 billion$23.74 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMRNBioMarin PharmaceuticalN/AN/AN/AN/AN/AJNJJohnson & Johnson$5.202.92%N/A55.61%64 YearsVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ALatest BMRN, VRTX, and JNJ DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/16/2025JNJJohnson & Johnsonquarterly$1.303.35%8/26/20258/26/20259/9/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMRNBioMarin Pharmaceutical0.105.563.60JNJJohnson & Johnson0.501.010.76VRTXVertex PharmaceuticalsN/A2.522.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMRNBioMarin Pharmaceutical98.71%JNJJohnson & Johnson69.55%VRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipBMRNBioMarin Pharmaceutical0.85%JNJJohnson & Johnson0.16%VRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMRNBioMarin Pharmaceutical3,040192.02 million190.38 millionOptionableJNJJohnson & Johnson138,1002.41 billion2.40 billionOptionableVRTXVertex Pharmaceuticals6,100256.39 million255.88 millionOptionableBMRN, VRTX, and JNJ HeadlinesRecent News About These CompaniesMIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $115.02 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX1 hour ago | marketbeat.comVertex Pharmaceuticals Incorporated $VRTX Stock Holdings Cut by DnB Asset Management ASSeptember 6 at 9:14 AM | marketbeat.comEFG Asset Management North America Corp. Has $4.43 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTXSeptember 6 at 8:45 AM | marketbeat.comCinctive Capital Management LP Acquires New Holdings in Vertex Pharmaceuticals Incorporated $VRTXSeptember 6 at 8:16 AM | marketbeat.comFederation des caisses Desjardins du Quebec Reduces Holdings in Vertex Pharmaceuticals Incorporated $VRTXSeptember 6 at 6:12 AM | marketbeat.comEP Wealth Advisors LLC Has $2.64 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTXSeptember 6 at 6:12 AM | marketbeat.comAlliancebernstein L.P. Increases Stock Position in Vertex Pharmaceuticals Incorporated $VRTXSeptember 5 at 7:36 AM | marketbeat.comAtalanta Sosnoff Capital LLC Sells 1,507 Shares of Vertex Pharmaceuticals Incorporated $VRTXSeptember 5 at 7:19 AM | marketbeat.comVertex Pharmaceuticals Incorporated $VRTX Shares Bought by Alyeska Investment Group L.P.September 5 at 6:45 AM | marketbeat.comAmundi Reduces Stake in Vertex Pharmaceuticals Incorporated $VRTXSeptember 5 at 6:44 AM | marketbeat.comRep. David Taylor Purchases Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)September 5 at 2:06 AM | marketbeat.comVertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Adage Capital Partners GP L.L.C.September 4 at 7:42 AM | marketbeat.comRaymond James Initiates Coverage of Vertex Pharmaceuticals (VRTX) with Market Perform RecommendationSeptember 4 at 4:22 AM | msn.comVertex Pharmaceuticals Incorporated (VRTX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptSeptember 3, 2025 | seekingalpha.comWhy Is Vertex (VRTX) Up 6.9% Since Last Earnings Report?September 3, 2025 | zacks.comHere’s Why Vertex Pharmaceuticals (VRTX) is on Loomis Sayles Growth Fund’s Detractors ListSeptember 3, 2025 | insidermonkey.comVertex teams with Enlaza to expand gene therapy optionsSeptember 3, 2025 | thepharmaletter.comTVertex Pharmaceuticals Incorporated $VRTX Shares Sold by PDT Partners LLCSeptember 3, 2025 | marketbeat.comVertex Pharmaceuticals Incorporated $VRTX Stock Position Reduced by GW Henssler & Associates Ltd.September 3, 2025 | marketbeat.com1248 Management LLC Cuts Holdings in Vertex Pharmaceuticals Incorporated $VRTXSeptember 3, 2025 | marketbeat.comPaloma Partners Management Co Invests $407,000 in Vertex Pharmaceuticals Incorporated $VRTXSeptember 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025JNJ Stock Surge Signals Confidence in New Growth PathBy Jeffrey Neal Johnson | August 25, 2025Worried About a Fading Rally? Consider These 3 Dividend StocksBy Dan Schmidt | August 11, 2025BMRN, VRTX, and JNJ Company DescriptionsBioMarin Pharmaceutical NASDAQ:BMRN$57.77 +1.02 (+1.80%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$57.38 -0.39 (-0.67%) As of 09/5/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.Johnson & Johnson NYSE:JNJ$178.20 -0.57 (-0.32%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$178.50 +0.31 (+0.17%) As of 09/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Vertex Pharmaceuticals NASDAQ:VRTX$396.12 -0.81 (-0.20%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$394.97 -1.15 (-0.29%) As of 09/5/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
